OpusPoint Partners is dedicated to launching new improvements in the areas of medicine and healthcare. The company’s financial investments in these areas will give emergent biotechnology and life science companies a head start to breaking new ground and the mentoring provided by OpusPoint Partners will pave an even path for these budding companies to reach the pinnacle of success.

It is the goal of OpusPoint Partners to find innovative alternatives in healthcare and medicine that are of betterment to the human race. Founded in 2009 by Michael Weiss and Lindsay Rosenwald, M.D., OpusPoint Partners has been on an influential and productive roll ever since. This is no surprise as both Weiss and Rosenwald are very knowledgeable in the spheres of biotech and life sciences, having founded and financed a multitude of like-minded research companies over the decades.

A solid case in point of the cofounders’ success in this realm can be noted with Lindsay Rosenwald’s creation of Cougar Biotechnology Inc. This Southern California biotech company primary focus is aimed at cancer drug research. Some of the drugs produced by this company showed promised during trials and garnered a great deal of attention from investors and researchers, including Johnson & Johnson. In 2009 the mega-conglomerate purchased Rosenwald’s biotech firm for approximately one billion dollars.

In order for OpusPoint Partners to have received the success that it has the company’s foundation would have to be knowingly built on transparency. Lindsay Rosenwald understands the importance of building an ethical groundwork with not only investors but also with the companies that he takes under the OpusPoint Partners wing. Full disclosure leads to comfortable investing and sustains the integrity of the company in the eyes of both financial backers and researchers alike.

Because of OpusPoint Partners strong ethical stance, the company is expanding to work with a variety of corporations, investors, and researchers who are itching for the opportunity to be included in the change that Lindsay Rosenwald and Michael Weiss are attempting to make in the realm of human health. Encouraging and financing emergent biotech companies is what Dr. Rosenwald does best, currently OpusPoint Partners is assisting nearly 20 life science and bio-tech companies attain their research goals and bring innovative drugs to trial in the hopes of making a monumental discovery in medicine.

With Lindsay Rosenwald at the helm of OpusPoint Partners, investors and biotech companies alike can feel confident that their venture needs are being met and that the company is copiously utilizing sound business acumen. Because of the company’s dedication to ethics within business Rosenwald and Weiss are able to offer their investors minimized investing risks that will continue to steadily grow over time. OpusPoint Partners ability to do this has been shown numerous times as the projections for the company’s growth has exceeded the projections for each year since its commencement.

Dr. Lindsay Rosenwald is ideally suited to co-lead OpusPoint Partners. His educational pursuits include obtaining a Bachelor of Science in Finance from Pennsylvania State University and then later a Doctor of Medicine from Temple University School of Medicine. Rosenwald has used this academic know how of two different industries to his advantage for the past 17 years as a biotechnology investor and trader on Wall Street as well as a founding numerous biotech companies.

Dr. Lindsay Rosenwald’s skills go beyond this; he has also effectively managed funds that ran into the billions for both the Aries Fund (1994 to 2007) and the Orion Fund (2002 to 2006). Under Rosenwald’s financial management the Aries Fund allocated in excess of one billion dollars for healthcare investments over the span of one year. The Orion Fund which is solely devoted to biotechnology investing also thrived under Dr. Rosenwald’s management.

The epicenter of OpusPoint Partners principles is to sustain a positive growth in the life science and biotech fields in manner that is genuine, honest, and promotes across the board ethical business standards. In today’s healthcare world where lines are sometimes blurred to maximize profit the OpusPoint Partners stands out as leader in business integrity and expects that the biotech companies that they back up to adhere to these same essential standards when it comes to research and drug clinical trials.

Lindsay Rosenwald and OpusPoint Partners intend to be a prominent force by being different from the typical biotechnology investing firms. The company, its investors, and employees all strive to maintain just dealings in all aspects of the business. And because of this the future indeed looks bright for the company, all of its associates, and the clinical sphere.

Michael Weiss and Dr. Lindsay Rosenwald both bring a lot to the table, their expertise has in the past helped to make great strides in the biotech and life science industry. With the over 40 years of combined experience both men offer investors and emergent companies in the biotech industry the assurance of quality, transparency, and innovation; all of which are key to bring about investment growth and industry change.

OpusPoint Partners with the expert guidance of Lindsay Rosenwald currently sponsors in excess of 20 up and coming biotech companies. This expansion in investments happened over a period of nearly two years and continues to steadily grow as well as yield encouraging returns in investments. It is the hope of all involved with OpusPoint Partners that true pioneering breakthroughs are made in medicine that will benefit all of society.

Dr. Lindsay Rosenwald dedicates a portion of his time outside of his occupation to the Republican Jewish Coalition sitting as a member on the Board of Directors. Rosenwald continues to actively develop his industry contacts in the biotechnology and financing realms. Sustained advancement of OpusPoint Partners is a likely reality under his proficient leadership.

Aries Fund · Republican Jewish Coalition